AURORA, Colo.–(BUSINESS WIRE)–Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Herpes simplex virus type 1 (HSV-1), the cause of the common cold sore, can spread into the central nervous system and preferences for certain parts of the brain. Study results published today in the Journal […]
CBSA has serious concerns about the Colorado Prescription Drug Affordability Board’s inconsistent approach to the preliminary data review process for drugs under affordability review in the first cohort. CBSA submitted a letter on Friday to […]
A number of flexibilities ushered in with the mandate are now permanent, but Thursday marks the official end of other policies. Click here to view original post
Copyright © 2026 Biotech Networks
